This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Boswellia

Boswellia serrata (Indian frankincense) gum resin extracts — particularly AKBA-enriched formulations like 5-Loxin and Aflapin — are a clean 5-LOX-inhibitor anti-inflammatory with the best clinical …

Aliases (1)

BOSWELLIA

TYPICAL DOSE

100 mg Aflapin/day OR 250 mg 5-Loxin/day, taken…

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is Boswellia?

Boswellia serrata (Indian frankincense) gum resin extracts — particularly AKBA-enriched formulations like 5-Loxin and Aflapin — are a clean 5-LOX-inhibitor anti-inflammatory with the best clinical evidence concentrated in knee osteoarthritis (meaningful WOMAC and VAS reductions across 7+ RCTs and multiple meta-analyses). Mechanism is complementary to NSAIDs (no COX inhibition, no gastric/cardiac liability) and complementary to curcumin (different pathway, often co-formulated). For a 20yo MMA athlete it's an OPTIONAL-ADD: a defensible 4-12 week course around grappling-heavy phases or after a hard sparring block, not a daily core item. Dose: 100-250 mg/day AKBA-enriched (5-Loxin / Aflapin) or 300-500 mg 2-3×/day standard 65% boswellic-acid extract, with food. Safety profile is excellent. Skip if pre-surgery (mild antiplatelet), pregnant, or on multiple CYP-metabolized prescriptions.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Research Indications

Most Effective

NF-κB inhibition

boswellic acids suppress TNF-α-induced NF-κB activation in macrophages and synoviocytes, dampening downstream cytokine cascades (IL-1β, I…

Effective

Cathepsin G and human leukocyte elastase inhibition

additional neutrophil-targeted anti-inflammatory.

Investigational

Complement C3 convertase inhibition

relevant in immune-complex driven inflammation.

Investigational

Topoisomerase I/II inhibition

in vitro anticancer signal (boswellic acid kills glioma and colon cancer cell lines in culture); clinically unproven but the basis for on…

Investigational

Glycosaminoglycan synthesis preservation

animal OA models show reduced cartilage matrix degradation, suggesting a structure-modifying signal beyond pure analgesia.

Peptide Interactions

Curcumin (especially BCM-95, Meriva phytosome, Theracurmin):

Synergistic

The signature pairing. Different pathways (curcumin: COX-2, NF-κB, multiple cytokines; boswellia: 5-LOX). Bioavailability appears mutually enhanced; both are…

Omega-3 (EPA/DHA):

Synergistic

EPA is the substrate competitor at COX/LOX pathways — high omega-3 shifts the precursor pool toward less inflammatory eicosanoids (PGE3, LTB5) while boswelli…

MSM + glucosamine + chondroitin:

Synergistic

Joint-stack classics; mechanism-different (cartilage matrix support vs anti-inflammatory). Reasonable layered stack for older OA users; less compelling for 2…

Collagen peptides (10-15 g/day with vitamin C):

Synergistic

Cartilage / tendon / ligament substrate; complementary, no interaction. Useful for grappling-heavy training given connective tissue load.

Vitamin D3 + K2:

Synergistic

General anti-inflammatory / immune-modulatory + bone health. No direct interaction; dopamine.club community data shows boswellia + D3 is the #1 combined stac…

NAC (already V4):

Synergistic

Glutathione precursor → reduces oxidative load that feeds into 5-LOX-product inflammation. Different mechanism, layered.

Tart cherry / pycnogenol / quercetin:

Synergistic

Polyphenol anti-inflammatory complements; clinical synergy unstudied but mechanistically reasonable.

High-dose NSAIDs daily

Avoid

not pharmacologically dangerous, just redundant and adds GI risk that boswellia alone wouldn't have. If actually using NSAIDs, the boswellia is wasted; if pi…

High-dose fish oil (>4 g/day) + aspirin

Avoid

combined antiplatelet load, monitor for bruising.

Anticoagulants (warfarin, DOACs):

Avoid

Theoretical additive antiplatelet effect; coordinate with prescribing clinician. Not absolutely contraindicated.

Multiple CYP3A4-narrow-window substrates

Avoid

boswellia has weak CYP inhibition signals in vitro (CYP3A4, CYP2C9, CYP2D6); clinical relevance is mostly minimal but worth flagging if stacking with sensiti…

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety

Common (>10% of users):

Mild GI upset — most common reported side effect. Nausea, acid reflux, mild dyspepsia, especially on empty stomach or at the upper dose range. The community-data block reports "digestive-upset" at n=9 (top side effect). Mitigation: take with food, drop dose 30-50%.
Mild diarrhea or stool changes in a minority of users, often resolving in 1-2 weeks.

Less common (1-10%):

Headache (n=3 community) — usually mild, resolves with dose reduction.
Skin rash / mild allergic reaction — rare but reported. Frankincense allergy is uncommon but possible.
Mild fatigue / drowsiness at higher doses (n=3).
Acid reflux / heartburn in users with GERD history.

Rare-serious (<1%):

Hepatotoxicity — extremely rare. The NIH LiverTox monograph classifies boswellia as low risk; a handful of case reports of mild transaminase elevation that resolved on discontinuation. No fulminant hepatotoxicity in the published literature.
Allergic skin reaction / contact dermatitis — frankincense resin can sensitize susceptible individuals.
Heavy menstrual bleeding — anecdotal reports from a small number of female users, possibly via mild antiplatelet effect. Not well characterized.
Hypoglycemia — rare; one case in the Madisch 2007 colitis trial that withdrew with hypoglycemia + dizziness + anorexia. Causality uncertain.

Mechanism-driven cautions:

Mild antiplatelet activity — 5-LOX inhibition reduces certain platelet aggregation pathways. Stop 5-7 days before surgery, dental extractions, or any procedure with bleeding risk. Caution if on aspirin, clopidogrel, warfarin, DOACs, or fish oil at high doses.
Pregnancy / uterine activity — animal models show some uterine stimulation; not recommended in pregnancy. Some Ayurvedic texts list it as an emmenagogue.
Breastfeeding — no safety data; avoid.

Comparison vs. NSAIDs (the practical comparison):

No COX inhibition → no GI ulcer/bleeding risk (vs. ibuprofen/naproxen).
No COX inhibition → no cardiovascular event elevation (vs. selective COX-2 inhibitors, ibuprofen at high chronic doses).
No renal prostaglandin suppression → no AKI risk in dehydrated training states (a meaningful issue for MMA cutting weight).
Cleaner long-term safety profile makes it the better tool for chronic low-grade inflammation; NSAIDs win for acute high-intensity pain.